We are committed to advancing our pipeline of early-and-late-stage drug candidates into novel treatments that may help people with immune-mediated diseases.
We recognize that people living with these diseases may need treatment options and may also be interested in the possibility of our investigational therapies being available to them upon request and prior to potential regulatory approval. Access to our investigational therapies must be fair and equitable, must safeguard the welfare of patients, and must not put at risk the completion of our ongoing research and development. We believe that sustainable long-term availability of our investigational therapies can best be achieved following demonstration of the investigational drug’s safety, tolerability, and effectiveness through controlled clinical trials, which may hopefully address the requirements of regulatory agencies.
Offering pre-approval access outside of a controlled clinical trial may jeopardize the conduct of our ongoing clinical trials and may also prevent or delay our broader clinical development programs, which would likely result in a setback to all patients in need. Accordingly, we are currently unable to provide access to our investigational therapies outside of our clinical trials. We are grateful to the people who are participating, or have participated, in our clinical trials.
More information on our clinical trials is available on www.clinicaltrials.gov